NCT04564092 - A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

September 4, 2021

Study Completion Date

September 4, 2021

Conditions

Healthy Subjects (HS)

Interventions

DRUG

DaTSCAN™ Ioflupane (123I) Injection

Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.

Trial Locations (1)

200025

Rujin hospital, affiliated to Shanghai Jiaotong University, School of Medicine, Huangpu